← Back to Search

GLP-1 Receptor Agonist

Retatrutide Dose 3 for Type 2 Diabetes

Phase 3

Recruiting

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 52

Awards & highlights

Study Summary

"This trial will test if retatrutide is better than a placebo for treating Type 2 Diabetes in people with kidney problems. Participants will be those who have not been able to control their blood sugar

Who is the study for?

This trial is for adults with Type 2 Diabetes who have moderate or severe kidney problems and whose blood sugar isn't well-controlled by long-acting insulin, possibly combined with metformin or SGLT2 inhibitors. Participants will be involved in the study for about 14 months and may need to attend up to 22 visits.Check my eligibility

What is being tested?

The trial is testing Retatrutide against a placebo to see if it's better at controlling blood sugar levels in people with Type 2 Diabetes who also have kidney issues. The participants' responses to these treatments are compared over time.See study design

What are the potential side effects?

While specific side effects of Retatrutide aren't listed here, common ones for diabetes medications can include low blood sugar, nausea, digestive issues, possible allergic reactions, and skin irritation at injection sites.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 52

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 52

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from Baseline in Hemoglobin A1c (HbA1c) (%)

Secondary outcome measures

Change from Baseline in Body Weight

Change from Baseline in Fasting Serum Glucose

Change from Baseline in Systolic Blood Pressure (SBP)

+10 more

Trial Design

4Treatment groups

Experimental Treatment

Placebo Group

Group I: Retatrutide Dose 3Experimental Treatment1 Intervention

Participants will receive retatrutide administered SC.

Group II: Retatrutide Dose 2Experimental Treatment1 Intervention

Participants will receive retatrutide administered SC.

Group III: Retatrutide Dose 1Experimental Treatment1 Intervention

Participants will receive retatrutide administered subcutaneously (SC).

Group IV: PlaceboPlacebo Group1 Intervention

Participants will receive placebo administered SC.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,620 Previous Clinical Trials

3,216,279 Total Patients Enrolled

Study DirectorEli Lilly and Company

1,348 Previous Clinical Trials

415,425 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

At how many distinct sites is this clinical trial being conducted?

"This clinical investigation is being conducted at Panthera Biopartners in Glasgow, Scotland, Centro Médico Viamonte in Buenos Aires, Ciudad Autónoma De Buenos Aires and the Clinical Research Institute of Arizona (CRI) in Sun City West, Arizona. Additionally, there are 39 other locations participating as well."

Answered by AI

Is the recruitment phase currently open for this clinical trial?

"According to the details on clinicaltrials.gov, recruitment for this specific trial is no longer ongoing. The initial posting date was 4/12/2024 with the latest update done on 3/1/2024. Despite this study being closed for enrollment, there are currently 1439 other active trials seeking participants."

Answered by AI

Has the first dosage of Retatrutide been officially approved by the FDA?

"According to our evaluation at Power, the safety rating for Retatrutide Dose 1 is graded as a 3. This assessment aligns with it being in Phase 3 of the trial, indicating existing efficacy data and robust safety records from previous rounds."

Answered by AI